Why Will Large Hospitals Drive Hospital Risk Management Market?

The major drivers in the global hospital risk management market are the high prevalence of long-term diseases and the increasing count of medical errors. In 2021, the market was valued at $1,115.4 million, and it is projected to touch $3,482.3 million by 2030. The market will advance at a 13.5% CAGR from 2021 to 2030. Medical errors lead to approximately 3 million deaths every year in comparison to mortality from malaria, HIV, and tuberculosis. Furthermore, extensive governmental support, the increasing integration of information technology in hospitals and clinics, and swift modernization will drive the market.

Furthermore, the second-largest shareholder in the hospital risk management market is the workflow management category, accounting for about one-fifth of the total revenue, in 2021. There is huge pressure on the healthcare infrastructure because of the surging incidence of long-term illnesses. Around 70% of the global deaths are because of chronic diseases per year, accounting for approximately the death of 40 million people each year. Apart from offering better effectiveness in medical data control, the category improves internal operations via automation.

By 2030, the biggest share in the hospital risk management market will be held by the large hospital category, accounting for approximately 60% of the total market share. This can be ascribed to a swift integration of EHRs in the healthcare centers., surging hospital expenditure, and an increasing count of large hospitals. To remove the medical errors, there is a dire need for hospital risk management to enhance the operations of EHR systems. The highest hospital bed density is witnessed in Japan with approximately 13 beds for every 1000 people.

In 2021, the global hospital risk management market was led by North America. This is because of the surging adoption of data science to ease the workflow in healthcare centers, the paradigm shift of the on-premises risk management to cloud-based solutions, and the surging count of market players in the U.S. There is a high investment in the healthcare sector due to rising medical errors. Approximately $40 billion is spent on patients bothered with medication errors.

Hence, an increasing count of medical errors and a high prevalence of long-term diseases will provide lucrative opportunities to the market players to gain a competitive edge.

Get More Details Hospital Risk Management Market Growth Factors, Company Profile Analysis

Read More

Increasing Research Activities Drive Development of Catalog Peptides

Every year, over 9.5 million people die of cancer each year, according to the World Health Organization (WHO). This is because either patients are diagnosed in later stages, or the drugs aren’t able to target tumors that well. A lot of cancers are formed due to the disruption in the pathways activated by peptides, which are essentially short chains of amino acids; a peptide of more than 50 amino acids is known as a protein. Since the establishment of the fact that protein pathway disruption is a potential cause of cancer, extensive research and development (R&D) has been put in to remedy this.

Browse detailed report with COVID-19 impact analysis on Catalog Peptides Market Competitive Landscape

Thus, with the rising prevalence of cancer and fruitful R&D, the catalog peptides market is predicted to grow from $238.4 million in 2018 to $332.1 million by 2024, at a 5.8% CAGR during 2019–2024 (forecast period). The term catalog peptide refers to the artificially synthesized peptide drugs which are readily available with biotechnology and pharmaceutical companies, as opposed to those that are customized as per user preference and the specific application.

Presently, North America makes the largest contribution to the catalog peptides market, owing to the presence of a number of biopharmaceutical companies, increasing R&D investments for widening the application area of such products, and adoption of improved technologies for manufacturing. Within the region, the U.S. consumes such drugs in higher amounts, owing to its increasing incidence of chronic diseases, especially cancer. Moreover, numerous drugs are receiving approvals from the Food and Drug Administration, which is leading to their rising availability for the treatment of various diseases.

Hence, with the rising R&D activities and prevalence of cancer, the demand for catalog peptides will also grow.

Read More